A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 )

Documenti analoghi

• Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
  di: Hyungwoo Cho, et al.
  Pubblicazione: (2024)
• Key phase diagram experiments and thermodynamic modeling of the ZnO‒B 2 O 3 , ZnO‒SiO 2 , and ZnO‒B 2 O 3 ‒SiO 2 systems
  di: Min‐Kyung Kim, et al.
  Pubblicazione: (2024)
• Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Center Study
  di: Jung Won Lee, et al.
  Pubblicazione: (2024)
• Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight
  di: Jae Hyeon Yu, et al.
  Pubblicazione: (2024)
• DiGIT: Multi-Dilated Gated Encoder and Central-Adjacent Region Integrated Decoder for Temporal Action Detection Transformer
  di: Kim, Ho-Joong, et al.
  Pubblicazione: (2025)